** Shares of drugmaker Emergent BioSolutions EBS.N rise ~2.9% to $9.68 premarket
** Emergent says it gained exclusive commercial rights to Hikma Pharmaceuticals' HIK.L opioid reversal nasal spray, Kloxxado
** Kloxxado rapidly reverses or blocks the effects of opioids, restoring normal respiration, especially when given within minutes of the first signs of an overdose
** Under the terms of the agreement, Hikma will continue to manufacture the nasal spray, while Emergent will handle distribution
** Up to last close, EBS up more than four-fold in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。